Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
45 participants
OBSERVATIONAL
2013-03-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study was to evaluate the influence of the use of lipid-lowering drugs in resting energy expenditure (REE) and total energy expenditure (TEE) in patients seropositive for HIV in treatment of lipodystrophy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nutritional Therapy Improves Dyslipidemia in HIV Infected Teenagers With Antiretroviral Treatment
NCT03021889
Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances
NCT02614027
Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
NCT00119405
Metabolic Abnormalities in HIV-infected Persons
NCT01612858
Adipose Tissue and Immune Activation in HIV
NCT04439448
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
TEE was measured by doubly labeled water (DLW) technique and an activity monitor based on accelerometry (AM).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LIPO-HIPO-
HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
No interventions assigned to this group
LIPO+HIPO-
HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
No interventions assigned to this group
LIPO+HIPO+
HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
use of lipid-lowering drugs.
The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
use of lipid-lowering drugs.
The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A cluster of differentiation 4 (CD4) T-cell count of \>200 cells/mm3
* Use of lipid-lowering drugs for at least 1 month (group HIV-seropositive with lipodystrophy and use of lipid-lowering)
Exclusion Criteria
* Thyroid disease
18 Years
60 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundação de Amparo à Pesquisa do Estado de São Paulo
OTHER_GOV
University of Sao Paulo General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAAE 01848612.1.0000.5440
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.